Allogene Therapeutics, Inc. (ALLO)
| Market Cap | 731.73M +221.7% |
| Revenue (ttm) | n/a |
| Net Income | -173.76M |
| EPS | -0.77 |
| Shares Out | 345.15M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,967,299 |
| Open | 2.110 |
| Previous Close | 2.100 |
| Day's Range | 2.065 - 2.190 |
| 52-Week Range | 0.990 - 4.460 |
| Beta | 0.47 |
| Analysts | Strong Buy |
| Price Target | 9.00 (+324.53%) |
| Earnings Date | Aug 12, 2026 |
About ALLO
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for ALLO stock is "Strong Buy." The 12-month stock price target is $9.0, which is an increase of 324.53% from the latest price.
News
Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update
SOUTH SAN FRANCISCO, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA...
Allogene gets RMAT, Fast Track designations for cemacabtagene ansegedleucel
Allogene Therapeutics (ALLO) announced that the FDA has granted Regenerative Medicine Advanced Therapy, or RMAT, and Fast Track designations to cemacabtagene ansegedleucel for the treatment of adult p...
Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma
FDA Granted RMAT Designation Based on ALPHA3 Trial Futility Analysis, Highlighting Cema-Cel's Potential to Transform Disease Treatment in First-Line LBCL Consolidation Cema-Cel Induced Rapid and Subst...
Allogene publishes Phase 1 data in Journal of Clinical Oncology
Allogene Therapeutics (ALLO) announced the publication of complete Phase 1 data from the TRAVERSE study of ALLO-316 in advanced or metastatic renal cell carcinoma in the Journal of Clinical Oncology.
Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors
ALLO-316 Achieved a 31% Confirmed Response Rate with the Recommended Phase 2 Regimen in Patients with Stage IV Renal Cell Carcinoma (RCC) with High CD70 Expression Single Dose of ALLO-316 Produced Dur...
Allogene Therapeutics Transcript: H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
The conference highlighted strong execution on pivotal cema-cel trials, rapid MRD testing adoption, and a sizable market opportunity. Interim data showed high MRD clearance and excellent safety, while ALLO-329's dual-targeting and Dagger technology drive innovation in autoimmune indications.
Allogene Therapeutics Transcript: AGM 2026
The meeting covered five key proposals, all of which were approved, including director elections, executive compensation, annual advisory votes, an increase in authorized shares, and auditor ratification. No questions were submitted, and forward-looking risks were acknowledged.
Allogene Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
Leadership is transitioning to Zach Roberts, with strong board continuity. The ALPHA3 study for cema-cel in MRD-positive LBCL shows promising efficacy and safety, targeting a $2.5–$3.5B market. The autoimmune ALLO-329 program is advancing, with key data expected in Q4.
Allogene Therapeutics says Zachary Roberts to succeed David Chang as CEO
Allogene Therapeutics (ALLO) announced that Dr. David Chang, M.D., Ph.D., will transition from his role as President and CEO, effective June 30, following eight years of leadership that established Al...
Allogene Therapeutics Announces Planned CEO Succession
SOUTH SAN FRANCISCO, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR...
Allogene Therapeutics Proxy statement: Proxy filing
Allogene Therapeutics filed a proxy statement on May 28, 2026, providing details for shareholder voting and corporate governance matters.
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR...
Allogene Therapeutics Proxy statement: Proxy filing
Allogene Therapeutics filed a proxy statement on May 21, 2026, providing details for shareholder voting and corporate governance matters.
Allogene Therapeutics Slides: Corporate presentation
Allogene Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 16, 2026.
Allogene Therapeutics ends China cell therapy deal with Overland
Allogene Therapeutics said on Wednesday it has ended a key partnership for developing cell therapies in parts of Asia and reworked its equity stake in partner Overland Therapeutics.
Allogene Therapeutics reports Q1 EPS (18c), consensus (18c)
The company had $266.9M in cash, cash equivalents, and investments as of March 31. In April, the company completed a public offering which resulted in aggregate gross proceeds of $200.4M,…
Allogene Therapeutics increases 2026 operating cash expense guidance
Based upon the company’s current forecast for the overall timing of the ALPHA3 program, it is modestly increasing its guidance for operating cash expense in 2026 from approximately $150M to…
Allogene Therapeutics Earnings Call Transcript: Q1 2026
Lead programs cema-cel and ALLO-329 showed strong interim efficacy and safety signals, with robust enrollment and global expansion. Financial position is solid, with a cash runway into Q1 2029 and increased operating expense guidance for 2026.
Allogene Therapeutics Earnings release: Q1 2026
Allogene Therapeutics released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Allogene Therapeutics Quarterly report: Q1 2026
Allogene Therapeutics has published its Q1 2026 quarterly earnings report on May 13, 2026.
Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update
SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR...
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
Conference Call and Webcast Scheduled for May 13, 2026 at 2 p.m. PT/5 p.m. ET SOUTH SAN FRANCISCO, Calif.
Allogene Therapeutics Proxy statement: Proxy filing
Allogene Therapeutics filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Allogene Therapeutics Proxy statement: Proxy filing
Allogene Therapeutics filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Allogene Therapeutics expands Phase 2 ALPHA3 trial to South Korea, Australia
Allogene Therapeutics (ALLO) announced that regulatory authorities in South Korea and Australia have cleared the Company to expand its pivotal Phase 2 ALPHA3 study evaluating cemacabtagene ansegedleuc...